
Release date: 2026-02-02 17:06:00 Article From: Lucius Laos Recommended: 11
Before starting elacestrant, discuss any questions or concerns with your medical team.
Take one 345 mg tablet once daily. Patients should continue treatment until disease progression or unacceptable toxic effects occur.
Dosing and Administration: Take one tablet once daily with food to reduce nausea. Swallow the tablet whole; do not chew, crush or split it.
Timing of Dosing: Try to take the medication at the same time each day. If a dose is missed, resume taking it at the regular time the next day without making up the missed dose.
The following suggestions will help you cooperate with the treatment better:
Bring a family member or friend with you to appointments for support;
Prepare in advance: take notes and make a list of questions to ask;
Ask members of your medical team to repeat or write down important information to ensure full understanding;
Record changes in your overall health, treatment-related side effects or adjustments to daily life before your next appointment.
It is essential to take elacestrant as directed every day. If you experience any side effects, inform your doctor or medical team promptly. They will assist you in managing the side effects and provide appropriate recommendations to ensure you receive optimal treatment.
If a dose is missed by more than 6 hours or vomiting occurs, skip the missed dose and take the next dose at the scheduled time the following day.
Avoid concomitant use with strong or moderate CYP3A4 inducers and inhibitors.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C); dose reduction is required in patients with moderate hepatic impairment (Child-Pugh Class B); no dose adjustment is needed in patients with mild hepatic impairment (Child-Pugh Class A).
In clinical trials, 3% of patients required a dose reduction of elacestrant due to adverse reactions.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:802025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3732024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:712025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:932025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:872025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:1022025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:992025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:992025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: